Kemp Dolliver

Stock Analyst at Brookline Capital

(0.54)
# 4,127
Out of 5,182 analysts
19
Total ratings
30.77%
Success rate
-13.1%
Average return

Stocks Rated by Kemp Dolliver

Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $5.00
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.53
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $5.83
Upside: +191.60%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.67
Upside: +285.44%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.20
Upside: +63.64%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.85
Upside: +1,845.95%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.22
Upside: +14,031.41%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $81.43
Upside: +22.80%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $5.92
Upside: +862.84%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.56
Upside: +876.56%
Initiates: Buy
Price Target: $19
Current: $6.63
Upside: +182.81%
Assumes: Buy
Price Target: $8
Current: $0.99
Upside: +706.45%
Initiates: Buy
Price Target: $5.65
Current: $0.34
Upside: +1,561.76%